Knight Therapeutics deal with Advaxis gets thumbs up at Laurentian


A licensing agreement between Knight Therapeutics (TSX:GUD) and Advaxis is getting the thumbs up from Laurentian Bank Seecurities analyst Joseph Walewicz. This morning, Knight announced it had entered into a licensing agreement in Canada to commercialize Advaxis’s product portfolio including its three lead drug candidates: axalimogene filolisbac (ADXS-HPV) for human papilloma virus-associated cancers, ADXS-PSA for […]

Tweed Marijuana set to become “dominant player” on Bedrocan acquisition, says M Partners


Tweed Marijuana’s (TSXV:TWD) acquisition of Bedrocan Cannabis creates a scaled medical marijuana entity that is still being undervalued by the market, says M Partners analyst Daniel Pearlstein. On Monday, shareholders of Bedrocan approved the proposed takeover of the company by Tweed, and the arrangement is expected to be completed this Friday. Tweed plans to hold […]

Halifax’s HealthQR Attracting Prominent Partners Ahead of Efficacy Testing


Halifax-based HealthQR, developers of an app that reminds people to take their prescription medications, is deepening their relationship with multi-national drug giant Pfizer while entering into a series of tests of the app’s effectiveness with Dalhousie and Mount Saint-Vincent Universities, according to an interview with the Halifax Chronicle-Herald. Three non-profits that specialize in varying chronic […]

Valeant buys “female Viagra” maker Sprout but market is not aroused


Shares of Valeant Pharmaceuticals (TSX:VRX) aren’t getting a lift from the company’s billion dollar purchase of Sprout Pharmaceuticals, maker of a treatment, Addyi, that is often referred to as the “female viagra”. Valeant today said it would pay approximately $1-billion for the Raleigh, North Carolina-based maker of treatments for female sexual health. “Delivering a first-ever […]

Cipher Pharmaceuticals gets price target cut at Euro Pacific Canada


A “noisy” quarter with several disappointments has Euro Pacific Canada analyst Doug Loe feeling a little less bullish on Cipher Pharmaceuticals (TSX:CPH, Nasdaq:CPHR). On Friday, Cipher Pharma reported its Q2, 2015 results. The company lost (U.S.) $558,000 on revenue of $8.8-million, a topline that was up 10% from the same period last year. The quarter […]

BioSyent gets price target cut at Cantor Fitzgerald Canada

Biosyent's leading brand is FeraMAX. It currently markets two formulations for the treatment of iron deficient anemia.

A topline miss in its second quarter results is typical of the “lumpiness” that Cantor Fitzgerald Canada analyst Scott Curtis expects from BioSyent (TSXV:RX) in the near term. Yesterday, BioSyent reported its Q2, 2015 results. The company earned $851,039 on revenue of $3.59-million. “For the first time, in June and July, 2015, the company’s sales […]

Merus Labs is a buy despite soft Q3, says Laurentian

Laurentian Bank Securities analyst Joseph Walewicz says there were some bright spots in Merus Labs's third quarter, including the performance of C.difficile treatment Vancocin.

Merus Labs’ (TSX:MSL) third quarter results were a downside surprise but the stock is still a buy, says Laurentian Bank Securities analyst Joseph Walewicz. Yesterday, shares of Merus fell after the company reported third quarter results that disappointed the street. The company lost $1.6-million on revenue of $9.5-million, a performance CEO Barry Fishman described as […]

Merus Labs falls after reporting “challenging” third quarter results


Shares of Merus Labs (TSX:MSL) are down today after the company reported third quarter results that disappointed the street. Merus lost $1.6-million on revenue of $9.5-million. “Our in-market prescription trends are tracking as expected for Emselex and Sintrom. However, two major factors impacted the lower-than-expected [third-quarter] 2015 financial results: (1) foreign exchange fluctuations and (2) […]

Homeopathy is a joke, says this Canadian educator


Its adherents swear by its effectiveness, but one noted Canadian educator is leaving no ambiguity about what he thinks of homeopathy. “It’s a joke, is what it is,” said Professor Joe Schwarcz, the head of McGill University’s Office for Science and Society and host of “The Dr. Joe Show” on Montreal’s CJAD. “Homeopathy has no […]

TSO3 is still undervalued, says M Partners

sterizone VP4

The ramp up in U.S. sales is just getting started for TSO3 (TSX:TOS), says M Partners analyst Daniel Pearlstein. Yesterday, TSO3 reported its Q2, 2015 results. The company lost $1.74-million on sales of $136,969. “During the quarter substantial progress was made on all fronts,” said CEO Ric Rumble. “Sales and service teams have been trained […]